Company

Okogen, Inc.

Okogen, Inc., founded in 2015 in Plano, develops ophthalmic treatments for acute infectious conjunctivitis.

About

Founded in 2015 in Plano, US, Okogen, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on acute infectious conjunctivitis, with a lead product in Phase 2B clinical trials. The company targets an annual USD 4.2 billion conjunctivitis market and aims to address the lack of approved therapies for adenoviral conjunctivitis. In November 2024 it raised USD 2.451 mn in a Series B round, with a company valuation of USD 4.270 mn. CEO Brian Strem and Joshua Moriarty lead the company.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in